ArticleBMC health services research2025
Electronic data sources for drug utilization research and healthcare decision-making in Mexico.
Article in BMC health services research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUnderstanding drug utilization is essential for informed decision-making in national healthcare and for enabling comparisons across countries. In Mexico, the limited research in this field may be attributed to the lack of awareness and accessibility of existing data sources. Addressing this gap requires a comprehensive inventory of data sources for Drug Utilization Research (DUR). The purpose of this study was to develop an inventory of electronic data sources available in Mexico for DUR, outlining their characteristics, strengths, and limitations.
methodsFrom 2019 to 2024, specialists in pharmacoepidemiology and healthcare systems research conducted online searches for DUR data sources, including official websites of the Mexican government and public health institutions. A literature review was also performed for country-specific data sources in articles published between 2000 and 2023. Data sources were independently searched, screened, and selected by independent reviewers, with disagreements resolved through consensus. A descriptive analysis of selected databases was conducted, focusing on accessibility, geographical coverage, data aggregation level, health sector type, data source type, and setting.
resultsThe analysis included twenty data sources, of which only four were publicly available. These databases offer insights into various aspects of drug utilization, primarily owned by social security institutions (twelve). Only four contain data from the private healthcare sector. Regarding data source type, five focused on procurement, twelve on prescription, two on pharmacovigilance, and one on drug disposal.
conclusionsMexico faces notable challenges in accessible data for DUR especially in non-social security institutions and the private sector. This study underscores the urgent need to improve healthcare data accessibility and research in Mexico, to drive evidence-informed decision-making regarding medicines utilization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.